Takeda Reacquires Rights to Diabetes Drug in Canada

25-Aug-2009 - Canada

Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (Pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of Actos, licensed the drug to Lilly as part of a worldwide agreement in 1999.

"Reacquiring the commercial rights to ACTOS is Takeda's first opportunity to establish a commercial presence in Canada," said Daaron Dohler, general manager at Takeda Canada. "It also underscores Takeda's ongoing efforts to reinforce our global operations and build a stronger presence in North America."

ACTOS was approved by Health Canada as monotherapy to decrease insulin resistance and blood glucose levels in patients with type 2 diabetes mellitus, in September 2000. Takeda has taken over responsibility for ACTOS in the Canadian market effective mid-June. The company already sells ACTOS in many other territories, including the United States, Japan and most of Europe.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances